Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Biomedicines|September 5, 2019
Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer TherapyVolker Schirrmacher, Stefaan van Gool, Wilfried Stuecker
Biomedicines|April 27, 2024
Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single InstitutionVolker Schirrmacher, Stefaan Van Gool, Wilfried Stuecker
International Journal of Molecular Sciences|November 11, 2022
Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular ImmunotherapyVolker Schirrmacher, Stefaan van Gool, Wilfried Stuecker
Biomedicines|July 29, 2020
Evidence-Based Medicine in Oncology: Commercial Versus Patient BenefitVolker Schirrmacher, Tobias Sprenger, Wilfried Stuecker, et al.
Cancers|December 30, 2020
Randomized Controlled Immunotherapy Clinical Trials for GBM ChallengedStefaan W Van Gool, Jennifer Makalowski, Simon Fiore, et al.
Genes and Immunity|February 17, 2022
Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patientsStefaan W Van Gool, Jennifer Makalowski, Michael Bitar, et al.
Cancers|February 25, 2023
Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute ExperienceStefaan W Van Gool, Jennifer Makalowski, Peter Van de Vliet, et al.
Medicines (Basel, Switzerland)|May 23, 2020
Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution ExperienceStefaan W Van Gool, Jennifer Makalowski, Erin R Bonner, et al.
Methods in Cell Biology|March 28, 2024
Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patientsStefaan W Van Gool, Peter Van de Vliet, Linde F C Kampers, et al.
Pageof 1